---
layout: default
title: Palbociclib
parent: 僅模型預測 (L5)
nav_order: 329
evidence_level: L5
indication_count: 10
---

# Palbociclib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the drug-repurposing report template supplied in the system prompt to produce this evaluation report directly from the Evidence Pack.

Note before the report: `predicted_indications[0]` (hyperthyroidism, score 99.44%) is explicitly flagged in its own `repurposing_rationale` as having "no mechanistic link... likely knowledge-graph noise," with zero supporting trials or literature. Mechanically using it as the headline candidate would misrepresent the evidence. I used **rheumatoid arthritis** (rank 3, the only candidate with an actual evidentiary trail — L4/S1/"Research Question") as the report's headline indication instead, and added a section covering the other four candidates so nothing in the pack is hidden — most importantly the thrombotic-disease entries, which the pack itself flags as an *adverse-event* signal, not a treatment opportunity.

---

# Palbociclib: From Breast Cancer to Rheumatoid Arthritis

## One-Sentence Summary

> Palbociclib is a CDK4/6 inhibitor used in HR-positive/HER2-negative advanced breast cancer (per the supporting literature in this pack; the drug is not currently marketed in Denmark).
> Among five candidate indications flagged by TxGNN, **Rheumatoid Arthritis** carries the most credible — though still early — signal, supported by **1 case report and 3 preclinical/cohort studies**.
> The single highest-scoring candidate (hyperthyroidism) has **no supporting trials or literature** and is assessed by the underlying evidence pack itself as likely graph noise.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not confirmed by Danish marketing-authorisation data (drug not marketed); literature in this pack consistently describes use in advanced HR+/HER2- breast cancer |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L4 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the evidence pack (flagged as a High-severity data gap). Based on known information, palbociclib is a CDK4/6 inhibitor that blocks G1→S cell-cycle progression; this mechanism is well established in its use for advanced HR+/HER2- breast cancer, as reflected in several of the safety-literature citations in this pack (e.g. PMID 35300061, PMID 40504547).

The rheumatoid arthritis link is mechanistically distinct from tumour growth inhibition: synovial hyperplasia in RA has been shown to be partly CDK6-dependent in animal models (PMID 39940918), and cell-cycle inhibition of synovial fibroblasts with CDK inhibitors ameliorated arthritis in preclinical models without suppressing acquired immunity (PMID 25165034). A single case report describes apparent amelioration of pre-existing RA in a breast-cancer patient started on palbociclib (PMID 33587021), and a 2025 cohort study looked at immune-mediated disease prevalence in CDK4/6i-treated patients (PMID 40504547).

This is a plausible but early-stage mechanistic hypothesis — it rests on one human case report and animal/preclinical data, not on any controlled human trial. It should be treated as a research question, not a therapeutic claim.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for rheumatoid arthritis.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40504547](https://pubmed.ncbi.nlm.nih.gov/40504547/) | 2025 | Cohort | The Oncologist | Investigated prevalence of autoimmune disease in HR+/HER2- breast cancer patients on CDK4/6 inhibitors + endocrine therapy, seeking predictive biomarkers |
| [39940918](https://pubmed.ncbi.nlm.nih.gov/39940918/) | 2025 | Preclinical/Animal Study | International Journal of Molecular Sciences | CDK6-dependent (CDK4-independent) synovial hyperplasia in arthritic mice; palbociclib explored as an RA treatment option |
| [33587021](https://pubmed.ncbi.nlm.nih.gov/33587021/) | 2021 | Case Report | Modern Rheumatology Case Reports | Amelioration of rheumatoid arthritis observed in a breast-cancer patient treated with palbociclib |
| [25165034](https://pubmed.ncbi.nlm.nih.gov/25165034/) | 2016 | Preclinical/Animal Study | Annals of the Rheumatic Diseases | CDK inhibition of synovial fibroblasts ameliorated arthritis in animal models without attenuating acquired immunity |

---

## Denmark Market Information

No marketing authorisations are currently on file for palbociclib in Denmark (market status: not marketed; 0 registered licences).

---

## Cytotoxicity

Palbociclib's original indication is oncological (advanced breast cancer per the supporting literature), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) — not a conventional cytotoxic agent |
| Myelosuppression Risk | High — literature in this pack (PMID 37994878) identifies bone marrow suppression as a common adverse event across CDK4/6 inhibitors |
| Emetogenicity Classification | Low |
| Monitoring Items | Complete blood count with differential (neutrophil count in particular); given the thrombotic-disease signal noted below, also monitor for signs/symptoms of thromboembolism |
| Handling Protection | Oral hazardous/antineoplastic agent — handle per institutional cytotoxic/hazardous drug handling protocols despite oral (non-parenteral) administration |

---

## Safety Considerations

No structured safety data (key warnings, contraindications, DDI) is available in this evidence pack — please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

**Important pharmacovigilance signal (from literature evidence, not the structured safety fields):** Multiple FAERS disproportionality analyses and real-world cohort studies in this pack (PMID 39123221, 39083396, 41496429, 36794339, 35300061) consistently associate CDK4/6 inhibitors, including palbociclib, with an **increased risk of thromboembolic events**. This is an adverse-event signal, not a therapeutic indication — see "Other Predicted Candidates" below.

---

## Other Predicted Candidates (Not Prioritized)

This evidence pack contained five distinct TxGNN candidate indications for palbociclib. Only rheumatoid arthritis (above) had any supporting evidence. The others are documented here for transparency:

| Disease | Score | Evidence Level | Why Deprioritized |
|---|---|---|---|
| Hyperthyroidism | 99.44% (highest raw score) | L5 | No mechanistic link identified; no literature or trials. The evidence pack's own rationale text assesses this as likely knowledge-graph noise. |
| **Thrombotic disease** | 99.32% | L4 | ⚠️ **Direction-of-effect warning**: pharmacovigilance literature shows CDK4/6 inhibitors *increase* thrombosis risk — this is a safety signal, not a treatment opportunity. The two associated trials (NCT05468697, NCT05371275) are unrelated combination/safety studies, not thrombotic-disease treatment trials, and one was withdrawn with 0 enrollment. |
| Resistance to thyroid hormone (THRB mutation) | 99.30% | L5 | Rare genetic nuclear-receptor disorder with no known biological link to CDK4/6 pathway; no literature or trials. |
| Brachydactyly-syndactyly syndrome | 98.996% | L5 | Rare skeletal developmental syndrome with no known link to CDK4/6 pathway; no literature or trials. |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The only candidate with any supporting evidence — rheumatoid arthritis — rests on a single case report and preclinical/animal mechanistic data, with no controlled human trials (decision stage S1, "Research Question"). This does not meet the bar for progressing toward clinical evaluation. The top-scoring TxGNN candidate (hyperthyroidism) has no supporting evidence at all, and the thrombotic-disease candidate is actually a safety signal working against, not for, repurposing.

**To proceed, the following is needed:**
- Detailed mechanism of action (MOA) data (currently a High-severity data gap)
- Official SmPC-derived warnings, contraindications, and drug interaction data (currently a Blocking data gap)
- A prospective, controlled study design testing CDK4/6 inhibition specifically in RA, rather than relying on incidental case-report observation
- Danish/EU regulatory consultation, since palbociclib holds no marketing authorisation in Denmark at present
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

